Wisdom of the Crowd: insights gained from comparing predicted and observed effects of blood pressure lowering strategies

Sonali R Gnanenthiran; Vivekanand Jha; Abdul Salam; Emily Atkins; Clara K Chow; Mark R Nelson; Mike Rakotz; Markus P Schlaich; Aletta E Schutte; Tim Usherwood; Anthony Rodgers

doi:10.1038/s41371-023-00816-y

Wisdom of the Crowd: insights gained from comparing predicted and observed effects of blood pressure lowering strategies

J Hum Hypertens. 2023 May;37(5):422-424. doi: 10.1038/s41371-023-00816-y. Epub 2023 Apr 11.

Authors

Sonali R Gnanenthiran¹, Vivekanand Jha^{2

3

4}, Abdul Salam^{4

5}, Emily Atkins^{1

6}, Clara K Chow⁶, Mark R Nelson⁷, Mike Rakotz⁸, Markus P Schlaich⁹, Aletta E Schutte¹, Tim Usherwood^{1

6}, Anthony Rodgers¹⁰

Affiliations

¹ The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
² The George Institute for Global Health, University of New South Wales, New Delhi, India.
³ School of Public Health, Imperial College, London, UK.
⁴ Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India.
⁵ The George Institute for Global Health, University of New South Wales, Hyderabad, India.
⁶ Westmead Applied Research Centre, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, NSW, Australia.
⁷ Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
⁸ American Medical Association, Chicago, IL, USA.
⁹ Dobney Hypertension Centre, Medical School, Royal Perth Hospital Unit, University of Western Australia, Perth, WA, Australia.
¹⁰ The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia. arodgers@georgeinstitute.org.

Abstract

In a first of its kind assessment in cardiovascular research, we assessed whether pooled cardiovascular expertise could accurately predict efficacy and tolerability for both a novel and an established treatment option. A survey was administered prior to the publication of the QUARTET (A Quadruple UltrA-low-dose tReatment for hypErTension) trial. QUARTET was a multicentre, double-blind, parallel-group, trial that randomised participants to initial treatment with either monotherapy or an ultra-low dose quadruple single pill combination for 12 weeks. Survey participants were asked to predict blood pressure (BP) at 12 weeks and 52 weeks for both groups.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Blood Pressure*
Humans
Hypertension* / therapy